AU2006249440C1 - Formulations of suberoylanilide hydroxamic acid and methods for producing same - Google Patents

Formulations of suberoylanilide hydroxamic acid and methods for producing same Download PDF

Info

Publication number
AU2006249440C1
AU2006249440C1 AU2006249440A AU2006249440A AU2006249440C1 AU 2006249440 C1 AU2006249440 C1 AU 2006249440C1 AU 2006249440 A AU2006249440 A AU 2006249440A AU 2006249440 A AU2006249440 A AU 2006249440A AU 2006249440 C1 AU2006249440 C1 AU 2006249440C1
Authority
AU
Australia
Prior art keywords
active ingredient
minutes
dissolved
pharmaceutical composition
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006249440A
Other languages
English (en)
Other versions
AU2006249440A1 (en
AU2006249440B2 (en
Inventor
Kimberly Gallagher
Craig Ikeda
Justin Moser
Pavol Rajniak
Robert A. Reed
Cindy Starbuck
Quingxi Wang
Jeannie Chow Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006249440(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of AU2006249440A1 publication Critical patent/AU2006249440A1/en
Application granted granted Critical
Publication of AU2006249440B2 publication Critical patent/AU2006249440B2/en
Priority to AU2009201652A priority Critical patent/AU2009201652B2/en
Priority to AU2009201650A priority patent/AU2009201650B2/en
Publication of AU2006249440C1 publication Critical patent/AU2006249440C1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2006249440A 2005-05-20 2006-05-16 Formulations of suberoylanilide hydroxamic acid and methods for producing same Active AU2006249440C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2009201652A AU2009201652B2 (en) 2005-05-20 2009-04-27 Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2009201650A AU2009201650B2 (en) 2005-05-20 2009-04-27 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US60/682,875 2005-05-20
US69312805P 2005-06-23 2005-06-23
US60/693,128 2005-06-23
PCT/US2006/018795 WO2006127321A2 (en) 2005-05-20 2006-05-16 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2009201652A Division AU2009201652B2 (en) 2005-05-20 2009-04-27 Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2009201650A Division AU2009201650B2 (en) 2005-05-20 2009-04-27 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Publications (3)

Publication Number Publication Date
AU2006249440A1 AU2006249440A1 (en) 2006-11-30
AU2006249440B2 AU2006249440B2 (en) 2009-03-12
AU2006249440C1 true AU2006249440C1 (en) 2009-08-13

Family

ID=37452585

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2006249440A Active AU2006249440C1 (en) 2005-05-20 2006-05-16 Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2009201650A Ceased AU2009201650B2 (en) 2005-05-20 2009-04-27 Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2009201652A Ceased AU2009201652B2 (en) 2005-05-20 2009-04-27 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2009201650A Ceased AU2009201650B2 (en) 2005-05-20 2009-04-27 Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2009201652A Ceased AU2009201652B2 (en) 2005-05-20 2009-04-27 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Country Status (20)

Country Link
US (4) US8093295B2 (OSRAM)
EP (2) EP1853245A2 (OSRAM)
JP (2) JP5264174B2 (OSRAM)
KR (2) KR100884500B1 (OSRAM)
AR (1) AR055953A1 (OSRAM)
AU (3) AU2006249440C1 (OSRAM)
BR (1) BRPI0605893A (OSRAM)
CA (1) CA2580367C (OSRAM)
CR (1) CR8912A (OSRAM)
DO (1) DOP2006000113A (OSRAM)
EC (1) ECSP077263A (OSRAM)
IL (1) IL181070A0 (OSRAM)
MA (1) MA28804B1 (OSRAM)
MX (1) MX2007002047A (OSRAM)
MY (1) MY144613A (OSRAM)
NI (1) NI200700031A (OSRAM)
NZ (2) NZ594669A (OSRAM)
PE (1) PE20061390A1 (OSRAM)
TW (2) TWI415603B (OSRAM)
WO (2) WO2006127319A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
AU2009305214B2 (en) * 2008-10-15 2015-06-25 Generics [Uk] Limited Process for the preparation of vorinostat
CA2744458A1 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
JP2012509929A (ja) * 2008-11-26 2012-04-26 ジェネリクス・（ユーケー）・リミテッド 多型
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
EP3484470A4 (en) * 2016-07-13 2020-02-26 Technion Research & Development Foundation Limited INHIBITORS OF HISTONE DEACETYLASE 4 CYTOPLASMIC COMPLEX FOR THE TREATMENT OR PREVENTION OF VASCULAR OR VALVULAR CALCIFICATION
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075839A2 (en) * 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US20040122101A1 (en) * 2002-03-04 2004-06-24 Miller Thomas A. Polymorphs of suberoylanilide hydroxamic acid

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
EP1123309A2 (en) 1998-10-13 2001-08-16 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptides and their use as histone deacetylase inhibitor
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
TR200201052T2 (tr) 1999-09-08 2003-01-21 Sloan-Kettering Institute For Cancer Research Yeni hücre farklılaştırıcı ajanlar sınıfı ve hıstone deacetylase inhibitörleri, ve burada kullanım yöntemleri
EP1748046A3 (en) 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
DE60143520D1 (de) 2000-03-24 2011-01-05 Methylgene Inc Inhibitoren der histon-deacetylase
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2001290131B2 (en) 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7199227B2 (en) * 2001-06-14 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding human histone deacetylase HDAC9c
AU2002340253C1 (en) * 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
EP1613592A4 (en) * 2003-04-01 2008-03-12 Sloan Kettering Inst Cancer HYDROXAMIC ACID COMPOUNDS AND METHODS OF USE THEREOF
RU2356547C2 (ru) * 2003-08-26 2009-05-27 Мерк ЭйчДиЭйСи Рисерч ЛЛС Способы лечения рака с использованием ингибиторов hdac
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
US20090227674A1 (en) 2005-08-18 2009-09-10 Richon Victoria M Combination methods fo saha and targretin for treating cancer
AU2006311808A1 (en) 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and bortezomib for treating cancer
CA2626679C (en) 2005-11-04 2011-08-16 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075839A2 (en) * 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US20040122101A1 (en) * 2002-03-04 2004-06-24 Miller Thomas A. Polymorphs of suberoylanilide hydroxamic acid

Also Published As

Publication number Publication date
EP2292221A2 (en) 2011-03-09
WO2006127319A2 (en) 2006-11-30
PE20061390A1 (es) 2007-01-15
US20100112046A1 (en) 2010-05-06
TWI365068B (en) 2012-06-01
US20100113829A1 (en) 2010-05-06
AU2009201650A1 (en) 2009-05-21
BRPI0605893A (pt) 2007-12-18
IL181070A0 (en) 2007-07-04
MA28804B1 (fr) 2007-08-01
AU2009201650B2 (en) 2011-09-15
NZ553204A (en) 2011-09-30
US20100119596A1 (en) 2010-05-13
EP1853245A2 (en) 2007-11-14
AU2009201652B2 (en) 2011-10-06
KR100993135B1 (ko) 2010-11-10
WO2006127319A3 (en) 2007-03-29
JP2011251985A (ja) 2011-12-15
AU2006249440A1 (en) 2006-11-30
WO2006127321A3 (en) 2007-03-22
US20080132575A1 (en) 2008-06-05
AR055953A1 (es) 2007-09-12
TWI415603B (zh) 2013-11-21
MX2007002047A (es) 2007-04-12
JP2008519081A (ja) 2008-06-05
WO2006127321A2 (en) 2006-11-30
US8093295B2 (en) 2012-01-10
KR20080113135A (ko) 2008-12-26
CR8912A (es) 2008-02-21
KR100884500B1 (ko) 2009-02-20
CA2580367C (en) 2012-08-21
MY144613A (en) 2011-10-04
NZ594669A (en) 2013-02-22
EP2292221A3 (en) 2011-08-10
AU2009201652A1 (en) 2009-05-21
AU2006249440B2 (en) 2009-03-12
TW201034660A (en) 2010-10-01
KR20070062505A (ko) 2007-06-15
US8450372B2 (en) 2013-05-28
NI200700031A (es) 2008-03-03
ECSP077263A (OSRAM) 2007-04-26
US8288440B2 (en) 2012-10-16
JP5308486B2 (ja) 2013-10-09
TW200727892A (en) 2007-08-01
AU2010201359A1 (en) 2010-04-29
CA2580367A1 (en) 2006-11-30
DOP2006000113A (es) 2006-10-31
JP5264174B2 (ja) 2013-08-14

Similar Documents

Publication Publication Date Title
AU2009201650B2 (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20120142770A1 (en) Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
EP2229941A1 (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20100035991A1 (en) Amide base salts of saha and polymorphis thereof
HK1072362B (en) Methods of inducing terminal differentiation

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 MAR 2009.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-INVENTOR TO READ FROM WANG, QINGXI TO WANG, QUINGXI AND DELETE CO-INVENTORS SELL, BRIAN; COHEN, BENJAMIN MAX; TUNG, HSIEN-HSIN; DIENEMANN, ERIK A.; MILLER, THOMAS A.; CAPODANNO, VINCENT R. AND COTE, AARON S..

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 JUN 2009.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 MAR 2009

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-INVENTOR FROM WANG, QINGXI TO WANG, QUINGXI AND DELETE CO-INVENTORS SELL, BRIAN; COHEN, BENJAMIN MAX; TUNG, HSIEN-HSIN; DIENEMANN, ERIK A.; MILLER, THOMAS A.; CAPODANNO, VINCENT R. AND COTE, AARON S.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 JUN 2009

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE FROM MERCK & CO., INC. TO MERCK SHARP & DOHME CORP.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JAN 2010.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JAN 2010

HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.